查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1866638

間質幹細胞：全球市佔率及排名、總收入及需求預測（2025-2031年）

Mesenchymal Stem Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 128 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球間質幹細胞市場預計在 2024 年達到 12.45 億美元，預計到 2031 年將達到 25.42 億美元，在 2025 年至 2031 年的預測期內，複合年成長率將達到 10.6%。

間質幹細胞（MSCs）是一種來自多種組織的多功能能幹細胞，包括骨髓、臍帶、脂肪組織和胎盤。它們具有強大的自我更新和多系分化潛能，能夠分化成成骨細胞、軟骨細胞、脂肪細胞和其他間質來源細胞。 MSCs具有低免疫抗原性、免疫調節活性和強大的細胞激素分泌能力，使其成為再生醫學、免疫療法和抗發炎治療的重要研究對象。隨著細胞培養技術、無血清培養基和符合GMP規範的生產過程的進步，MSCs正從臨床前研究走向臨床應用，並被廣泛應用於整形外科疾病、心血管疾病、自體免疫疾病、腫瘤學和組織工程等領域。間質幹細胞（MSC）產業涵蓋上游工程細胞獲取、大規模培養、冷凍保存、物流和治療產品開發，使MSC成為全球細胞和基因治療（CGT）市場的基礎，也是精準醫療的關鍵推動力。這引起了全球投資者和監管機構的廣泛關注。

間質幹細胞（MSC）產業正進入加速成長階段，這主要得益於全球細胞和基因治療研發的快速發展、人口老化帶來的醫療保健需求成長以及對再生醫學的支持性政策。根據公開的年度報告，正在進行的MSC臨床試驗數量持續增加，僅2024年，美國和中國就註冊了300多項試驗，涵蓋神經系統疾病、代謝性疾病和自體免疫疾病。世界各國政府正大力投資創新，並透過支持符合GMP標準的生產設施和品質標準化來降低技術壁壘。跨國製藥公司與區域性CDMO（合約研發生產機構）之間的頻繁合作，正在促進工業化生產和快速市場滲透。隨著來自亞洲和中東的投資不斷增加，MSC有望成為全球精準醫療和個人化醫療發展的重要策略重點。

儘管間質幹細胞（MSC）產業發展迅速，但仍面臨許多挑戰，例如細胞獲取複雜、大規模生產困難、臨床通訊協定不一致以及監管要求存在區域差異。許多公司缺乏成熟的製程最佳化和批次間一致性經驗，導致高成本且商業化週期長。智慧財產權壁壘、跨境臨床核准以及全球監管的複雜性進一步增加了進入門檻，尤其對中小企業而言更是如此。市場不確定性，例如資本市場波動和醫療報銷政策，也是風險因素。如何在嚴格的品質標準、成本效益和價格可負擔之間取得平衡，對於塑造競爭格​​局至關重要。

市場需求正迅速從基礎研究轉向商業性臨床應用。隨著免疫療法、組織工程和個人化醫療的發展，間質幹細胞（MSC）的應用範圍不斷擴大，涵蓋心血管修復、軟骨再生、自體免疫疾病管理、抗衰老齡化療法和醫學美容等領域。與mRNA和基因編輯技術的融合，為高品質、客製化的MSC產品創造了巨大的發展機會。企業和研究機構正在加速推動自動化和數位化流程控制，以提高產品一致性並降低成本。人口老化、慢性病高發生率以及相關政策的支持，將使MSC在未來五年內成為全球細胞治療市場的核心成長引擎。

本報告旨在對全球間間質幹細胞市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名，並依地區/國家、類型和應用進行分析。

本報告以銷售收入為指標，間質幹細胞市場規模、估算和預測進行了呈現，以2024年為基準年，並包含了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定業務/成長策略、評估市場競爭、分析自身在當前市場中的地位，並就間質幹細胞做出明智的商業決策。

市場區隔

公司

  • CellResearch
  • StemCord
  • Cytopeutics
  • CryoCord
  • Cell Malaysia
  • Bangkok Stem Cell
  • Vinmec Stem Cell Institute
  • ProSTEM
  • Cryoviva
  • StemCells21
  • Lonza
  • Thermo Fisher Scientific
  • PromoCell
  • Stemcell Technologies
  • Bio-Techne
  • ATCC
  • Merck

依類型分類的區隔市場

  • 臍帶間質幹細胞
  • 骨髓間質幹細胞
  • 胎盤來源的間質幹細胞
  • 其他

應用領域

  • 調查
  • 疾病治療
  • 美容與抗衰老
  • 保持

依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Mesenchymal Stem Cells was estimated to be worth US$ 1245 million in 2024 and is forecast to a readjusted size of US$ 2542 million by 2031 with a CAGR of 10.6% during the forecast period 2025-2031.

Mesenchymal Stem Cells (MSCs) are multipotent stem cells derived from various tissues such as bone marrow, umbilical cord, adipose tissue, and placenta. They possess strong self-renewal and multilineage differentiation capabilities, enabling them to differentiate into osteoblasts, chondrocytes, adipocytes, and other mesenchymal-origin cells. MSCs are characterized by low immunogenicity, immunomodulatory effects, and robust cytokine secretion, making them a key focus in regenerative medicine, immune therapy, and anti-inflammatory treatment. With advancements in cell culture techniques, serum-free media, and GMP-compliant manufacturing, MSCs are transitioning from preclinical research to clinical applications, finding broad use in orthopedic disorders, cardiovascular diseases, autoimmune conditions, oncology, and tissue engineering. The MSC industry spans upstream cell sourcing, large-scale expansion, cryopreservation, logistics, and therapeutic product development, positioning MSCs as a cornerstone of the global cell and gene therapy (CGT) market and a critical driver of precision medicine, drawing strong attention from investors and regulatory authorities worldwide.

The mesenchymal stem cell (MSC) industry is entering a phase of accelerated growth, driven by the global boom in cell and gene therapy R&D, rising healthcare needs of aging populations, and supportive regenerative medicine policies. According to public annual reports, the number of ongoing MSC clinical trials continues to grow, with over 300 trials registered in the U.S. and China in 2024 alone, covering neurological, metabolic, and autoimmune disorders. Governments are investing heavily in innovation, supporting GMP-compliant manufacturing facilities and quality standardization, reducing technical barriers. Frequent collaborations between multinational pharmaceutical companies and regional CDMOs are facilitating industrial-scale production and rapid market penetration. With increasing investments from Asia and the Middle East, MSCs are poised to become a strategic focus in global precision and personalized medicine development.

Despite rapid growth, the MSC industry faces challenges such as complex cell sourcing, difficulties in large-scale manufacturing, inconsistent clinical protocols, and varying regulatory requirements across regions. Many companies lack mature experience in process optimization and batch consistency, resulting in high costs and extended commercialization timelines. Intellectual property barriers, cross-border clinical certifications, and global regulatory complexities further increase entry thresholds, particularly for small and mid-sized players. Market uncertainties, including fluctuations in capital markets and healthcare reimbursement policies, also pose risks. Balancing strict quality standards, cost efficiency, and accessible pricing will be critical for shaping the competitive landscape.

Demand is rapidly shifting from basic research to commercial clinical applications. The growth of immunotherapy, tissue engineering, and personalized medicine is expanding MSC use cases, including cardiovascular repair, cartilage regeneration, autoimmune disease management, anti-aging therapies, and medical aesthetics. Emerging integration with mRNA technology and gene editing is creating vast opportunities for premium, customized MSC products. Companies and research institutions are accelerating automation and digital process control to enhance product consistency and reduce costs. The convergence of aging demographics, chronic disease prevalence, and supportive policy frameworks positions MSCs as a central growth engine in the global cell therapy market over the next five years.

This report aims to provide a comprehensive presentation of the global market for Mesenchymal Stem Cells, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Mesenchymal Stem Cells by region & country, by Type, and by Application.

The Mesenchymal Stem Cells market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesenchymal Stem Cells.

Market Segmentation

By Company

  • CellResearch
  • StemCord
  • Cytopeutics
  • CryoCord
  • Cell Malaysia
  • Bangkok Stem Cell
  • Vinmec Stem Cell Institute
  • ProSTEM
  • Cryoviva
  • StemCells21
  • Lonza
  • Thermo Fisher Scientific
  • PromoCell
  • Stemcell Technologies
  • Bio-Techne
  • ATCC
  • Merck

Segment by Type

  • Umbilical Cord Derived MSC
  • Bone Marrow Derived MSC
  • Placenta Derived MSC
  • Other

Segment by Application

  • Research
  • Disease Treatment
  • Beauty and Anti-aging
  • Storage

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Mesenchymal Stem Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Mesenchymal Stem Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Mesenchymal Stem Cells in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Mesenchymal Stem Cells Product Introduction
  • 1.2 Global Mesenchymal Stem Cells Market Size Forecast (2020-2031)
  • 1.3 Mesenchymal Stem Cells Market Trends & Drivers
    • 1.3.1 Mesenchymal Stem Cells Industry Trends
    • 1.3.2 Mesenchymal Stem Cells Market Drivers & Opportunity
    • 1.3.3 Mesenchymal Stem Cells Market Challenges
    • 1.3.4 Mesenchymal Stem Cells Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Mesenchymal Stem Cells Players Revenue Ranking (2024)
  • 2.2 Global Mesenchymal Stem Cells Revenue by Company (2020-2025)
  • 2.3 Key Companies Mesenchymal Stem Cells Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Mesenchymal Stem Cells Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Mesenchymal Stem Cells
  • 2.6 Mesenchymal Stem Cells Market Competitive Analysis
    • 2.6.1 Mesenchymal Stem Cells Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Mesenchymal Stem Cells Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cells as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Umbilical Cord Derived MSC
    • 3.1.2 Bone Marrow Derived MSC
    • 3.1.3 Placenta Derived MSC
    • 3.1.4 Other
  • 3.2 Global Mesenchymal Stem Cells Sales Value by Type
    • 3.2.1 Global Mesenchymal Stem Cells Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Mesenchymal Stem Cells Sales Value, by Type (2020-2031)
    • 3.2.3 Global Mesenchymal Stem Cells Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Research
    • 4.1.2 Disease Treatment
    • 4.1.3 Beauty and Anti-aging
    • 4.1.4 Storage
  • 4.2 Global Mesenchymal Stem Cells Sales Value by Application
    • 4.2.1 Global Mesenchymal Stem Cells Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Mesenchymal Stem Cells Sales Value, by Application (2020-2031)
    • 4.2.3 Global Mesenchymal Stem Cells Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Mesenchymal Stem Cells Sales Value by Region
    • 5.1.1 Global Mesenchymal Stem Cells Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Mesenchymal Stem Cells Sales Value by Region (2020-2025)
    • 5.1.3 Global Mesenchymal Stem Cells Sales Value by Region (2026-2031)
    • 5.1.4 Global Mesenchymal Stem Cells Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.2.2 North America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.3.2 Europe Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Mesenchymal Stem Cells Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.5.2 South America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Mesenchymal Stem Cells Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Mesenchymal Stem Cells Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Mesenchymal Stem Cells Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.3.2 United States Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.4.2 Europe Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.5.2 China Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.6.2 Japan Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.7.2 South Korea Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Mesenchymal Stem Cells Sales Value, 2020-2031
    • 6.9.2 India Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Mesenchymal Stem Cells Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 CellResearch
    • 7.1.1 CellResearch Profile
    • 7.1.2 CellResearch Main Business
    • 7.1.3 CellResearch Mesenchymal Stem Cells Products, Services and Solutions
    • 7.1.4 CellResearch Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.1.5 CellResearch Recent Developments
  • 7.2 StemCord
    • 7.2.1 StemCord Profile
    • 7.2.2 StemCord Main Business
    • 7.2.3 StemCord Mesenchymal Stem Cells Products, Services and Solutions
    • 7.2.4 StemCord Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.2.5 StemCord Recent Developments
  • 7.3 Cytopeutics
    • 7.3.1 Cytopeutics Profile
    • 7.3.2 Cytopeutics Main Business
    • 7.3.3 Cytopeutics Mesenchymal Stem Cells Products, Services and Solutions
    • 7.3.4 Cytopeutics Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Cytopeutics Recent Developments
  • 7.4 CryoCord
    • 7.4.1 CryoCord Profile
    • 7.4.2 CryoCord Main Business
    • 7.4.3 CryoCord Mesenchymal Stem Cells Products, Services and Solutions
    • 7.4.4 CryoCord Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.4.5 CryoCord Recent Developments
  • 7.5 Cell Malaysia
    • 7.5.1 Cell Malaysia Profile
    • 7.5.2 Cell Malaysia Main Business
    • 7.5.3 Cell Malaysia Mesenchymal Stem Cells Products, Services and Solutions
    • 7.5.4 Cell Malaysia Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Cell Malaysia Recent Developments
  • 7.6 Bangkok Stem Cell
    • 7.6.1 Bangkok Stem Cell Profile
    • 7.6.2 Bangkok Stem Cell Main Business
    • 7.6.3 Bangkok Stem Cell Mesenchymal Stem Cells Products, Services and Solutions
    • 7.6.4 Bangkok Stem Cell Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Bangkok Stem Cell Recent Developments
  • 7.7 Vinmec Stem Cell Institute
    • 7.7.1 Vinmec Stem Cell Institute Profile
    • 7.7.2 Vinmec Stem Cell Institute Main Business
    • 7.7.3 Vinmec Stem Cell Institute Mesenchymal Stem Cells Products, Services and Solutions
    • 7.7.4 Vinmec Stem Cell Institute Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Vinmec Stem Cell Institute Recent Developments
  • 7.8 ProSTEM
    • 7.8.1 ProSTEM Profile
    • 7.8.2 ProSTEM Main Business
    • 7.8.3 ProSTEM Mesenchymal Stem Cells Products, Services and Solutions
    • 7.8.4 ProSTEM Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.8.5 ProSTEM Recent Developments
  • 7.9 Cryoviva
    • 7.9.1 Cryoviva Profile
    • 7.9.2 Cryoviva Main Business
    • 7.9.3 Cryoviva Mesenchymal Stem Cells Products, Services and Solutions
    • 7.9.4 Cryoviva Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Cryoviva Recent Developments
  • 7.10 StemCells21
    • 7.10.1 StemCells21 Profile
    • 7.10.2 StemCells21 Main Business
    • 7.10.3 StemCells21 Mesenchymal Stem Cells Products, Services and Solutions
    • 7.10.4 StemCells21 Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.10.5 StemCells21 Recent Developments
  • 7.11 Lonza
    • 7.11.1 Lonza Profile
    • 7.11.2 Lonza Main Business
    • 7.11.3 Lonza Mesenchymal Stem Cells Products, Services and Solutions
    • 7.11.4 Lonza Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Lonza Recent Developments
  • 7.12 Thermo Fisher Scientific
    • 7.12.1 Thermo Fisher Scientific Profile
    • 7.12.2 Thermo Fisher Scientific Main Business
    • 7.12.3 Thermo Fisher Scientific Mesenchymal Stem Cells Products, Services and Solutions
    • 7.12.4 Thermo Fisher Scientific Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Thermo Fisher Scientific Recent Developments
  • 7.13 PromoCell
    • 7.13.1 PromoCell Profile
    • 7.13.2 PromoCell Main Business
    • 7.13.3 PromoCell Mesenchymal Stem Cells Products, Services and Solutions
    • 7.13.4 PromoCell Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.13.5 PromoCell Recent Developments
  • 7.14 Stemcell Technologies
    • 7.14.1 Stemcell Technologies Profile
    • 7.14.2 Stemcell Technologies Main Business
    • 7.14.3 Stemcell Technologies Mesenchymal Stem Cells Products, Services and Solutions
    • 7.14.4 Stemcell Technologies Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Stemcell Technologies Recent Developments
  • 7.15 Bio-Techne
    • 7.15.1 Bio-Techne Profile
    • 7.15.2 Bio-Techne Main Business
    • 7.15.3 Bio-Techne Mesenchymal Stem Cells Products, Services and Solutions
    • 7.15.4 Bio-Techne Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Bio-Techne Recent Developments
  • 7.16 ATCC
    • 7.16.1 ATCC Profile
    • 7.16.2 ATCC Main Business
    • 7.16.3 ATCC Mesenchymal Stem Cells Products, Services and Solutions
    • 7.16.4 ATCC Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.16.5 ATCC Recent Developments
  • 7.17 Merck
    • 7.17.1 Merck Profile
    • 7.17.2 Merck Main Business
    • 7.17.3 Merck Mesenchymal Stem Cells Products, Services and Solutions
    • 7.17.4 Merck Mesenchymal Stem Cells Revenue (US$ Million) & (2020-2025)
    • 7.17.5 Merck Recent Developments

8 Industry Chain Analysis

  • 8.1 Mesenchymal Stem Cells Industrial Chain
  • 8.2 Mesenchymal Stem Cells Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Mesenchymal Stem Cells Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Mesenchymal Stem Cells Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Mesenchymal Stem Cells Market Trends
  • Table 2. Mesenchymal Stem Cells Market Drivers & Opportunity
  • Table 3. Mesenchymal Stem Cells Market Challenges
  • Table 4. Mesenchymal Stem Cells Market Restraints
  • Table 5. Global Mesenchymal Stem Cells Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Mesenchymal Stem Cells Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Mesenchymal Stem Cells Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Mesenchymal Stem Cells Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Mesenchymal Stem Cells
  • Table 10. Global Mesenchymal Stem Cells Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cells as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Mesenchymal Stem Cells Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Mesenchymal Stem Cells Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Mesenchymal Stem Cells Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Mesenchymal Stem Cells Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Mesenchymal Stem Cells Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Mesenchymal Stem Cells Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Mesenchymal Stem Cells Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Mesenchymal Stem Cells Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Mesenchymal Stem Cells Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Mesenchymal Stem Cells Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Mesenchymal Stem Cells Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Mesenchymal Stem Cells Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Mesenchymal Stem Cells Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Mesenchymal Stem Cells Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Mesenchymal Stem Cells Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Mesenchymal Stem Cells Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Mesenchymal Stem Cells Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Mesenchymal Stem Cells Sales Value, (2026-2031) & (US$ Million)
  • Table 31. CellResearch Basic Information List
  • Table 32. CellResearch Description and Business Overview
  • Table 33. CellResearch Mesenchymal Stem Cells Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Mesenchymal Stem Cells Business of CellResearch (2020-2025)
  • Table 35. CellResearch Recent Developments
  • Table 36. StemCord Basic Information List
  • Table 37. StemCord Description and Business Overview
  • Table 38. StemCord Mesenchymal Stem Cells Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Mesenchymal Stem Cells Business of StemCord (2020-2025)
  • Table 40. StemCord Recent Developments
  • Table 41. Cytopeutics Basic Information List
  • Table 42. Cytopeutics Description and Business Overview
  • Table 43. Cytopeutics Mesenchymal Stem Cells Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Cytopeutics (2020-2025)
  • Table 45. Cytopeutics Recent Developments
  • Table 46. CryoCord Basic Information List
  • Table 47. CryoCord Description and Business Overview
  • Table 48. CryoCord Mesenchymal Stem Cells Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Mesenchymal Stem Cells Business of CryoCord (2020-2025)
  • Table 50. CryoCord Recent Developments
  • Table 51. Cell Malaysia Basic Information List
  • Table 52. Cell Malaysia Description and Business Overview
  • Table 53. Cell Malaysia Mesenchymal Stem Cells Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Cell Malaysia (2020-2025)
  • Table 55. Cell Malaysia Recent Developments
  • Table 56. Bangkok Stem Cell Basic Information List
  • Table 57. Bangkok Stem Cell Description and Business Overview
  • Table 58. Bangkok Stem Cell Mesenchymal Stem Cells Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Bangkok Stem Cell (2020-2025)
  • Table 60. Bangkok Stem Cell Recent Developments
  • Table 61. Vinmec Stem Cell Institute Basic Information List
  • Table 62. Vinmec Stem Cell Institute Description and Business Overview
  • Table 63. Vinmec Stem Cell Institute Mesenchymal Stem Cells Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Vinmec Stem Cell Institute (2020-2025)
  • Table 65. Vinmec Stem Cell Institute Recent Developments
  • Table 66. ProSTEM Basic Information List
  • Table 67. ProSTEM Description and Business Overview
  • Table 68. ProSTEM Mesenchymal Stem Cells Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Mesenchymal Stem Cells Business of ProSTEM (2020-2025)
  • Table 70. ProSTEM Recent Developments
  • Table 71. Cryoviva Basic Information List
  • Table 72. Cryoviva Description and Business Overview
  • Table 73. Cryoviva Mesenchymal Stem Cells Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Cryoviva (2020-2025)
  • Table 75. Cryoviva Recent Developments
  • Table 76. StemCells21 Basic Information List
  • Table 77. StemCells21 Description and Business Overview
  • Table 78. StemCells21 Mesenchymal Stem Cells Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Mesenchymal Stem Cells Business of StemCells21 (2020-2025)
  • Table 80. StemCells21 Recent Developments
  • Table 81. Lonza Basic Information List
  • Table 82. Lonza Description and Business Overview
  • Table 83. Lonza Mesenchymal Stem Cells Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Lonza (2020-2025)
  • Table 85. Lonza Recent Developments
  • Table 86. Thermo Fisher Scientific Basic Information List
  • Table 87. Thermo Fisher Scientific Description and Business Overview
  • Table 88. Thermo Fisher Scientific Mesenchymal Stem Cells Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Thermo Fisher Scientific (2020-2025)
  • Table 90. Thermo Fisher Scientific Recent Developments
  • Table 91. PromoCell Basic Information List
  • Table 92. PromoCell Description and Business Overview
  • Table 93. PromoCell Mesenchymal Stem Cells Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Mesenchymal Stem Cells Business of PromoCell (2020-2025)
  • Table 95. PromoCell Recent Developments
  • Table 96. Stemcell Technologies Basic Information List
  • Table 97. Stemcell Technologies Description and Business Overview
  • Table 98. Stemcell Technologies Mesenchymal Stem Cells Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Stemcell Technologies (2020-2025)
  • Table 100. Stemcell Technologies Recent Developments
  • Table 101. Bio-Techne Basic Information List
  • Table 102. Bio-Techne Description and Business Overview
  • Table 103. Bio-Techne Mesenchymal Stem Cells Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Bio-Techne (2020-2025)
  • Table 105. Bio-Techne Recent Developments
  • Table 106. ATCC Basic Information List
  • Table 107. ATCC Description and Business Overview
  • Table 108. ATCC Mesenchymal Stem Cells Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Mesenchymal Stem Cells Business of ATCC (2020-2025)
  • Table 110. ATCC Recent Developments
  • Table 111. Merck Basic Information List
  • Table 112. Merck Description and Business Overview
  • Table 113. Merck Mesenchymal Stem Cells Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Mesenchymal Stem Cells Business of Merck (2020-2025)
  • Table 115. Merck Recent Developments
  • Table 116. Key Raw Materials Lists
  • Table 117. Raw Materials Key Suppliers Lists
  • Table 118. Mesenchymal Stem Cells Downstream Customers
  • Table 119. Mesenchymal Stem Cells Distributors List
  • Table 120. Research Programs/Design for This Report
  • Table 121. Key Data Information from Secondary Sources
  • Table 122. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Mesenchymal Stem Cells Product Picture
  • Figure 2. Global Mesenchymal Stem Cells Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Mesenchymal Stem Cells Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Mesenchymal Stem Cells Report Years Considered
  • Figure 5. Global Mesenchymal Stem Cells Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Mesenchymal Stem Cells Revenue in 2024
  • Figure 7. Mesenchymal Stem Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Umbilical Cord Derived MSC Picture
  • Figure 9. Bone Marrow Derived MSC Picture
  • Figure 10. Placenta Derived MSC Picture
  • Figure 11. Other Picture
  • Figure 12. Global Mesenchymal Stem Cells Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 13. Global Mesenchymal Stem Cells Sales Value Market Share by Type, 2024 & 2031
  • Figure 14. Product Picture of Research
  • Figure 15. Product Picture of Disease Treatment
  • Figure 16. Product Picture of Beauty and Anti-aging
  • Figure 17. Product Picture of Storage
  • Figure 18. Global Mesenchymal Stem Cells Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 19. Global Mesenchymal Stem Cells Sales Value Market Share by Application, 2024 & 2031
  • Figure 20. North America Mesenchymal Stem Cells Sales Value (2020-2031) & (US$ Million)
  • Figure 21. North America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Europe Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Europe Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Asia Pacific Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Asia Pacific Mesenchymal Stem Cells Sales Value by Region (%), 2024 VS 2031
  • Figure 26. South America Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. South America Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Middle East & Africa Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Middle East & Africa Mesenchymal Stem Cells Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Key Countries/Regions Mesenchymal Stem Cells Sales Value (%), (2020-2031)
  • Figure 31. United States Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 32. United States Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 33. United States Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 34. Europe Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Europe Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 36. Europe Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 37. China Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 38. China Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 39. China Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 40. Japan Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 41. Japan Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 42. Japan Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 43. South Korea Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 44. South Korea Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 45. South Korea Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 46. Southeast Asia Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 47. Southeast Asia Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 48. Southeast Asia Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 49. India Mesenchymal Stem Cells Sales Value, (2020-2031) & (US$ Million)
  • Figure 50. India Mesenchymal Stem Cells Sales Value by Type (%), 2024 VS 2031
  • Figure 51. India Mesenchymal Stem Cells Sales Value by Application (%), 2024 VS 2031
  • Figure 52. Mesenchymal Stem Cells Industrial Chain
  • Figure 53. Mesenchymal Stem Cells Manufacturing Cost Structure
  • Figure 54. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 55. Bottom-up and Top-down Approaches for This Report
  • Figure 56. Data Triangulation
  • Figure 57. Key Executives Interviewed